Illumina, Inc. $ILMN Shares Purchased by National Pension Service

National Pension Service boosted its stake in Illumina, Inc. (NASDAQ:ILMN) by 18.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,886 shares of the life sciences company’s stock after buying an additional 8,602 shares during the period. National Pension Service’s holdings in Illumina were worth $7,199,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in ILMN. Rothschild Investment LLC increased its holdings in shares of Illumina by 8.7% during the fourth quarter. Rothschild Investment LLC now owns 2,907 shares of the life sciences company’s stock valued at $381,000 after purchasing an additional 232 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Illumina by 217.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 5,047 shares of the life sciences company’s stock valued at $662,000 after purchasing an additional 3,457 shares during the period. Jupiter Asset Management Ltd. increased its holdings in shares of Illumina by 54.4% during the fourth quarter. Jupiter Asset Management Ltd. now owns 271,354 shares of the life sciences company’s stock valued at $35,591,000 after purchasing an additional 95,594 shares during the period. Intech Investment Management LLC increased its holdings in shares of Illumina by 1,175.6% during the fourth quarter. Intech Investment Management LLC now owns 36,303 shares of the life sciences company’s stock valued at $4,762,000 after purchasing an additional 33,457 shares during the period. Finally, Baker Avenue Asset Management LP increased its holdings in shares of Illumina by 14.9% during the fourth quarter. Baker Avenue Asset Management LP now owns 4,399 shares of the life sciences company’s stock valued at $577,000 after purchasing an additional 570 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CAO Scott D. Ericksen sold 1,500 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total value of $225,150.00. Following the completion of the transaction, the chief accounting officer owned 14,946 shares in the company, valued at $2,243,394.60. This trade represents a 9.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $98,400.00. Following the completion of the transaction, the insider owned 21,568 shares of the company’s stock, valued at $3,450,880. This trade represents a 2.77% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,002,371 shares of company stock worth $155,472,900. Company insiders own 2.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ILMN. Robert W. Baird set a $137.00 price target on Illumina in a report on Friday, February 6th. Piper Sandler lowered their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. Canaccord Genuity Group lowered their price target on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a report on Friday, May 1st. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a report on Thursday, May 14th. Finally, JPMorgan Chase & Co. raised their price target on Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Seven research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Illumina has an average rating of “Hold” and an average target price of $138.38.

Illumina Trading Up 0.9%

NASDAQ:ILMN opened at $164.40 on Tuesday. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 1-year low of $78.79 and a 1-year high of $165.97. The firm has a market capitalization of $24.87 billion, a price-to-earnings ratio of 29.89, a price-to-earnings-growth ratio of 2.70 and a beta of 1.42. The stock has a fifty day simple moving average of $134.48 and a 200 day simple moving average of $132.39.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the company posted $0.97 EPS. Illumina’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Sell-side analysts forecast that Illumina, Inc. will post 5.2 earnings per share for the current year.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and kept a Buy rating, signaling continued confidence in the company’s upside potential and valuation. Benzinga article
• Positive Sentiment: Integrated DNA Technologies said its oncology research workflows are now optimized on Illumina software, which could support broader adoption of Illumina’s ecosystem and strengthen its positioning in cancer research tools. Business Wire article
• Neutral Sentiment: Chief accounting officer Scott D. Ericksen sold a small number of shares under a pre-arranged Rule 10b5-1 plan; while routine, it adds to recent insider selling activity. SEC filing
• Negative Sentiment: Director Keith A. Meister sold a very large block of Illumina shares in multiple transactions around May 28-June 1, reducing his stake materially. Large insider sales can weigh on sentiment even when they do not necessarily reflect operational weakness. SEC filing

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.